As the world races to find a vaccine for COVID-19, our colleague Dr Cem Gun, an Emergency Medicine Physician at Acıbadem University Atakent Hospital, has bravely volunteered for the country’s first clinical trial. On 9 October, he was administered the first dose of a COVID-19 vaccine developed in China and approved for trial by the Health Institutes of Turkey, at a high-key milestone event.
On why he volunteered for this trial, Dr Cem Gun said, “As a healthcare worker, I fall into the high-risk group for COVID-19 infection. I decided to be vaccinated not only to protect myself but also my patients and loved ones. I made this decision with peace of mind as it is a controlled trial; it is currently in Phase 3, making it a tested and safe vaccine.”
The vaccine will be administered in two doses, and volunteers will be monitored on its effectiveness over a year.
The World Bank has approved US$12 billion in financing to help developing countries buy and distribute COVID-19 vaccines, tests and treatments, aiming to support the vaccination of up to 1 billion people.
Related Stories
Project Renaissance at Mount Elizabeth Hospital, Where Legacy Meets the Future of Care
Over a span of 1,095 days, Project Renaissance marked a significant chapter in the evolution of Mount Elizabeth Hospital, one of Singapore’s most established private healthcare institutions. Conceived as a strategic transformation rather than a conventional refurbishment, the initiative sought to position the hospital for the demands of a rapidly changing healthcare landscape.
IHH Healthcare North Asia Strengthens Integrated Care Through Strategic Partnership
IHH Malaysia Partners Libyan Government for Medical Referrals
IHH Healthcare Malaysia signed a Memorandum of Understanding (MOU) with The Government of Libya on 9 February, establishing a structured medical referral pathway for Libyan civil servants requiring specialist treatment at 18 hospitals across IHH’s Malaysian network.
Agilus Diagnostics Expands Access to Next-Generation Precision Genomics
Agilus Diagnostics, a subsidiary of Fortis Healthcare, has installed the Illumina NovaSeq X sequencing platform at its Mumbai reference laboratory, marking a major step forward for precision genomics in India.
Mount Elizabeth Hospitals Celebrate 97 Wins at Singapore Health Quality Service Awards 2026
